Clinical Trial Update: Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating anti-PD-1 re-challenge after immune priming with ipilimumab and radiotherapy in advanced non-small cell lung cancer. The study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anti-PD-1 therapy
• ipilimumab (ipilimumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: ACTIVE_NOT_RECRUITING